Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluphenazine Enanthate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.66 |
| ▸ | FPR2 | P25090 | 12/20 | 0.69 |
| ▸ | RAD52 | P43351 | 3/20 | 0.67 |
| ▸ | DRD1 | P21728 | 3/20 | 0.66 |
| ▸ | HRH1 | P35367 | 3/20 | 0.66 |
| ▸ | DRD3 | P35462 | 3/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.66 |
| ▸ | DRD5 | P21918 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5803456 | 1.00 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| Fluphenazine Decanoate SCHEMBL29563075 | 1.00 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| SCHEMBL5801488 | 1.00 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| Fluphenazine Enanthate SCHEMBL29389566 | 1.00 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| Fluphenazine Decanoate SCHEMBL41288 | 1.00 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| SCHEMBL5802453 | 1.00 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| SCHEMBL5802291 | 1.00 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| SCHEMBL5800312 | 1.00 | FPR2 (0.69) | FPR2RAD52DRD2DRD1HRH1 | |
| Fluphenazine Decanoate SCHEMBL3714532 | 0.99 | FPR2 (0.68) | FPR2RAD52DRD2DRD1HRH1 | |
| Fluphenazine Decanoate SCHEMBL15533373 | 0.99 | FPR2 (0.68) | FPR2RAD52DRD2DRD1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1743 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218623-A1 | SALTS OF NEUROCEUTICALS AND USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2023-07-13 | — | — | US | claimed |
| EP-4146656-A1 | SALTS OF NEUROCEUTICALS AND USES THEREOF | Syneurx International (Taiwan) Corp. (TW) | 2023-03-15 | — | — | EP | claimed |
| WO-2021224830-A1 | SALTS OF NEUROCEUTICALS AND USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (CN) | 2021-11-11 | — | — | WO | claimed |
| EP-3643298-A1 | IN SITU PHASE CHANGE GEL SUSTAINED-RELEASE SYSTEM FOR SMALL MOLECULE DRUG AND PREPARATION METHOD THEREOF | Sichuan University (CN) | 2020-04-29 | — | — | EP | claimed |
| US-20200069583-A1 | IN SITU PHASE CHANGE GEL SUSTAINED-RELEASE SYSTEM FOR SMALL MOLECULE DRUG AND PREPARATION METHOD THEREOF | SICHUAN UNIVERSITY (CN) | 2020-03-05 | — | — | US | claimed |
| WO-2019178267-A2 | INDUCTIVE REGENERATION OF THE AIRWAY BY TRANSCRIPTIONAL FACTOR MODULATION OF GLANDULAR MYOEPITHELIAL STEM CELLS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-09-19 | — | — | WO | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| CN-102670518-A | Preparation method for insoluble spherical medical granules | QILU PHARMACEUTICAL CO LTD | 2012-09-19 | — | — | CN | claimed |
| EP-2432535-A2 | DRY POWDER INHALERS | 3M Innovative Properties Company (US) | 2012-03-28 | — | — | EP | claimed |
| US-8088814-B2 | Administering a cyclooxygenase inhibitor; treating schizophrenia, delusional disorders, affective disorders, autism or tic disorders | MUELLER NORBERT (DE) | 2012-01-03 | — | — | US | claimed |
| US-6420351-B1 | ADMINISTERING MIXTURE OF ALANINE, SERINE, METHYLGLYCINE AND CYCLOSERINE | THE GENERAL HOSPTIAL CORPORATION | 2002-07-16 | — | — | US | claimed |
| JP-2002511409-A | — | — | 2002-04-16 | — | — | JP | claimed |
| US-20020035145-A1 | Methods for treating neuropsychiatric disorders | THE GENERAL HOSPITAL CORPORATION | 2002-03-21 | — | — | US | claimed |
| US-6228875-B1 | ADMINISTERING DERIVATIVE OF ALANINE OR SERINE AS AGONIST OF NMDA RECEPTOR; ALZHEIMER*S DISEASE, PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS, SCHIZOPHRENIA; COGNITION ACTIVATORS | THE GENERAL HOSPITAL CORPORATION | 2001-05-08 | — | — | US | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| EP-1073432-A2 | USE OF GLYCINE SITE AGONISTS OR GLYCINE UPTAKE INHIBITORS FOR TREATING NEUROPSYCHIATRIC DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2001-02-07 | — | — | EP | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| WO-1999052519-A2 | METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 1999-10-21 | — | — | WO | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218623-A1 | SALTS OF NEUROCEUTICALS AND USES THEREOF | SLC1A2, GABRA6, GABRA2 | DRD2 1923/4885FPR2 3363/4885RAD52 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.